Evidence map›Paper›PMID 31367816›Full record

ArticleDoklady. Biochemistry and biophysics2019

Thapsigargin, Inhibitor of Sarco-Endoplasmic Ca

A P Kotnova, B M Lyanova, E A Dukhanina, T N Portseva, Yu V Ilyin, S G Georgieva, A G Stepchenko, E V Pankratova

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. CaCancers · 2021
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

A P KotnovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia. alina_kotnova@mail.ru.
B M LyanovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
E A DukhaninaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
T N PortsevaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
Yu V IlyinEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
S G GeorgievaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
A G StepchenkoEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
E V PankratovaEngelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russia.
Engelhardt Institute of Molecular Biology · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thapsigargin (SERCA ATPase inhibitor) inhibited the S100A4 metastatic marker expression in MDA-MB231 breast cancer cells. We found that S100A4 gene transcription is regulated by Ca

Indexed as

Breast NeoplasmsCalcium-Transporting ATPasesCell Line, TumorEnzyme InhibitorsGene Expression Regulation, NeoplasticHumansS100 Calcium-Binding Protein A4Sarcoplasmic ReticulumThapsigarginCalcium-Transporting ATPasesEnzyme InhibitorsS100 Calcium-Binding Protein A4Thapsigargin

Identifiers

PMID31367816
OpenAlexW2951105693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.